Our pipeline

We are advancing a pipeline that builds on our expertise in nVNS therapy. Take a look at what we’re working on and where it is in development.

US pipeline clinical development

The development plan draws on a significant amount of pre-clinical and clinical work that has been generated over the past several decades by researchers using VNS technologies.

Preclinical/Pilot Trials

We work with various institutes and organizations to investigate what disorders nVNS could impact.

Pivotal Trials

Studies intended to provide scientific evidence of the safety and efficacy of gammaCore in a particular disease and population.

FDA Clearance

FDA reviews clinical data and determines whether to clear gammaCore for commercialization.

Commercial Launch

Marketing of gammaCore to the intended audience.

Preclinical/Pilot Trials
Pivotal Trials
FDA Clearance
Commercial Launch
Neurology
Episodic cluster headache: Acute treatment
100% Complete 2Q '17
Migraine: Acute treatment
100% Complete 3Q '18
Cluster headache: Prevention
100% Complete 1Q '19
Migraine: Prevention
100% Complete 1Q '20
Migraine in adolescents
10% Complete
Post Traumatic Headache
10% Complete
Acute Stroke
10% Complete
Subarachnoid Hemorrhage
10% Complete
Parkinson's Disease
10% Complete
Post Traumatic Stress Disorder
10% Complete
Preclinical/Pilot Trials
Pivotal Trials
FDA Clearance
Commercial Launch
Pulmonology
Respiratory distress in patients with COVID-19
100% Complete 3Q '20
Symptomatic improvement in reactive airway disease
14% Complete

Commercialized indications for Europe

gammaCore is indicated for the following conditions:

CE marks for the EU/EFTA/EEA and UK

  • Treatment or prevention of symptoms of reactive airway disease, including asthma, bronchoconstriction, exercise-induced bronchospasm, and COPD.

  • Acute and/or prophylactic treatment of primary headache (migraine, cluster headache, and hemicrania continua) and medication overuse headache in adults.

  • Adjunctive therapy for adults to reduce the symptoms of certain anxiety and depression conditions (including panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder, and major depressive disorder).

  • Adjunctive therapy in the prevention of partial onset and generalized seizures associated with epilepsy in adults.

  • Adjunctive therapy for adults to reduce the symptoms of gastric motility disorders and irritable bowel syndrome (including nausea, vomiting, bloating/distention, early satiety, and abdominal pain).

nVNS therapy

Vagus nerve stimulation is a breakthrough technology that helps control multiple disorders.

Culture of innovation

Innovation permeates every aspect of our work.